EGFR and neoplasm: To improve the clinical benefit for EGFR-TKI resistant NSCLC patients, anti-Vascular Endothelial Growth Factor (VEGF) agent was attempted to combine with immunotherapy based on the finding about the synergistic anti-tumor effect with PD-1 inhibitor (Hegde et al., 2018).